Realfiction (REALFI) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
28 May, 2026Executive summary
Revenue for Q1-2026 was TSEK 811, down 7% year-over-year, reflecting a shift toward DPT commercialization and reduced legacy product focus.
Gross profit margin improved to 60.7% from 56.2% year-over-year due to a different sales mix.
Operating result improved to TSEK -5,347 from TSEK -7,337 year-over-year, driven by cost reductions.
Strategic review initiated to explore partnerships, joint ventures, or potential sale to accelerate DPT commercialization.
Liquidity remains a concern, with operations funded only until late summer 2026 without new capital.
Financial highlights
Net revenue: TSEK 811 (Q1-2025: TSEK 874).
Gross profit: TSEK 492 (Q1-2025: TSEK 491); gross margin: 60.7% (Q1-2025: 56.2%).
Result after financial items: TSEK -6,511 (Q1-2025: TSEK -8,409).
Earnings per share: SEK -0.27 (Q1-2025: -0.42).
Cash flow from operating activities: TSEK -4,214 (Q1-2025: TSEK -6,893).
Equity: TSEK 42,464 (Q1-2025: TSEK 39,953).
Outlook and guidance
Liquidity expected to last until late summer 2026 without additional capital or commercial inflows.
Material uncertainty exists regarding going concern due to loan covenant-related repayments and lack of commercial DPT agreements.
Management is pursuing additional financing and strategic alternatives.
Latest events from Realfiction
- Sharp revenue decline and liquidity risks as focus shifts to DPT commercialization.REALFI
Q4 202531 Mar 2026 - Sharp revenue drop in Q3 as DPT sales paused; capital raised to support DPT commercialization.REALFI
Q3 202527 Nov 2025 - SEK 50 million rights issue supports commercialization of advanced glasses-free 3D display tech.REALFI
Status Update23 Nov 2025 - DPT commercialization advances with improved margins and new funding, despite lower revenue.REALFI
Q2 202528 Jul 2025 - Q3-2024 saw record DPT-driven revenue growth and strong gross margins, with liquidity secured.REALFI
Q3 202413 Jun 2025 - Q2-2024 saw strong revenue growth and DPT licensing talks nearing a breakthrough.REALFI
Q2 202413 Jun 2025 - DPT commercialization accelerates with new funding and industry milestones despite lower revenue.REALFI
Q1 20256 Jun 2025 - Revenue surged and DPT commercialization advanced with a pivotal license agreement.REALFI
Q4 20245 Jun 2025